Use of injectable CAB/RPV LA as replacement ART in virally suppressed adults with HIV / Elliot DeHaan [and 7 others] ; developed by the New York State Department of Health (NYSDOH) AIDS Institute (AI) Clinical Guidelines Program
This guideline was developed by the New York State Department of Health (NYSDOH) AIDS Institute (AI). Its purpose is to provide healthcare practitioners with information on the use of injectable long-acting cabotegravir/rilpivirine (CAB/RPV LA) as replacement therapy for adults (≥18 years old) with HIV who are virally suppressed (HIV RNA level <50 copies/mL) [FDA 2021]. The goal is to ensure that clinicians understand:1. The risks and benefits of switching to injectable antiretroviral therapy (ART)2. How to engage patients in shared decision-making regarding treatment3. How to develop protocols within their institution or medical practice to deliver injectable ART based on currently available evidence from published clinical trial data..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
July 2021 |
|---|---|
| Erschienen: |
Albany, N.Y.: New York State Department of Health AIDS Institute ; July 2021 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
DeHaan, Elliot [VerfasserIn] |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed September 15, 2021) |
|---|
| Umfang: |
1 online resource (1 PDF file (18 pages)) ; illustrations |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773181300 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773181300 | ||
| 003 | DE-627 | ||
| 005 | 20230428011858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773181300 | ||
| 035 | |a (DE-599)KEP06872196X | ||
| 035 | |a (NCBI)9918250165606676 | ||
| 035 | |a (EBP)06872196X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a DeHaan, Elliot |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of injectable CAB/RPV LA as replacement ART in virally suppressed adults with HIV |c Elliot DeHaan [and 7 others] ; developed by the New York State Department of Health (NYSDOH) AIDS Institute (AI) Clinical Guidelines Program |
| 264 | 1 | |a [Albany, N.Y.] |b New York State Department of Health AIDS Institute |c July 2021 | |
| 300 | |a 1 online resource (1 PDF file (18 pages)) |b illustrations | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed September 15, 2021) | ||
| 520 | |a This guideline was developed by the New York State Department of Health (NYSDOH) AIDS Institute (AI). Its purpose is to provide healthcare practitioners with information on the use of injectable long-acting cabotegravir/rilpivirine (CAB/RPV LA) as replacement therapy for adults (≥18 years old) with HIV who are virally suppressed (HIV RNA level <50 copies/mL) [FDA 2021]. The goal is to ensure that clinicians understand:1. The risks and benefits of switching to injectable antiretroviral therapy (ART)2. How to engage patients in shared decision-making regarding treatment3. How to develop protocols within their institution or medical practice to deliver injectable ART based on currently available evidence from published clinical trial data. | ||
| 650 | 2 | |a HIV Infections |x drug therapy |0 http://id.nlm.nih.gov/mesh/D015658Q000188 | |
| 650 | 2 | |a Rilpivirine |x therapeutic use |0 http://id.nlm.nih.gov/mesh/D000068696Q000627 | |
| 650 | 2 | |a Anti-HIV Agents |x therapeutic use |0 http://id.nlm.nih.gov/mesh/D019380Q000627 | |
| 650 | 2 | |a Drug Combinations |0 http://id.nlm.nih.gov/mesh/D004338 | |
| 650 | 2 | |a Sustained Virologic Response |0 http://id.nlm.nih.gov/mesh/D000072230 | |
| 655 | 2 | |a Practice Guideline |0 http://id.nlm.nih.gov/mesh/D017065 | |
| 710 | 2 | |a Clinical Guidelines Program, |e VerfasserIn |4 aut | |
| 710 | 2 | |a New York (State). |b AIDS Institute. |e VerfasserIn |4 aut | |
| 710 | 2 | |a New York (State). |b AIDS Institute. |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK572795/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994078466 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994004713 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999780983 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995672337 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987670738 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987758562 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK572795/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK572795/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK572795/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK572795/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK572795/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||